糖尿病微循环障碍临床用药合理性评价  

Evaluation of the rationality of clinical medication in diabetic microcirculation disorder

作　　者：田霞 魏菊红 TIAN Xia;WEI Juhong(First People′s Hospital of Changshou City,Changshu Hospital Affiliated to Su Zhou University,Changshu 215500,China)

机构地区：[1]常熟市第一人民医院,苏州大学附属常熟医院,江苏常熟215500

出　　处：《实用医学杂志》2018年第9期1524-1528,共5页The Journal of Practical Medicine

摘　　要：目的评估糖尿病微循环障碍临床用药的合理性。方法抽取医院2016年7-12月诊断为2型糖尿病并进入临床路径的成人患者359例,对其改善微循环药物的临床应用情况进行统计分析,以使用率、联合用药率、品种选择、药物利用指数(DUI)、使用强度等作为评判标准。结果改善微循环药使用率94.43%,联合用药率73.75%,品种选择以活血化瘀类中药注射剂和血管扩张剂为主,DUI均在0.9~1.1范围内,使用强度177.82 DDD。结论该院糖尿病微循环障碍临床用药存在不规范性,用药指征和联合用药指征控制不严,治疗方案存在不合理性,需进一步加强管理。Objective To study the rationality about the application of clinical medication for diabeticmicrocirculation disorderturbance in a general hospital of level Ⅱ in Changshu. Methods Three hundred andfifty-nine patients with T2 DM who received the clinical pathway treatment were enrolled in this study in a generalhospital of level II in Changshu from July to December 2016. The statistical analysis was performed on the clinicalapplication of microcirculation-improving drugs. The selection of microcirculation-improving drugs,the drug utiliza-tion index（DUI）,the intensity of microcirculation-improving drugs and the rate of drug combination were used asthe evaluation criteria. Results The utilization rate of microcirculation-improving drugs was 94.43 %,and thecombination rate was 73.75 %.The selection of microcirculation-improving drugs was the traditional Chinesemedicine injections which activated blood circulation and vasodilators,with the DUI ranged from 0.9 to 1.1,andthe intensity of microcirculation-improving drugs was 177.82 DDD. Conclusion The application of the clinicalmedication for the diabetic microcirculation disturbance was not standard,as a result,the indications of medica-tion were not clear,and the indications of drug combination were not controlled strictly,the therapeutic regimenwas unreasonable,and further management should be strengthened.

关 键 词：糖尿病微循环障碍 微循环改善药 合理用药 

分 类 号：R969.3[医药卫生—药理学]